181
Participants
Start Date
June 2, 2022
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
Bexmarilimab
Intravenous
Azacitidine
As per label, subcutaneous
Venetoclax
Oral
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Tampere University Hospital, Tampere
Kuopio University Hospital, Kuopio
University of Texas, MD Anderson Cancer Center, Houston
Oulu University Hospital, Oulu
City of Hope National Medical Center, Duarte
Yale Cancer Center, New Haven
Helsinki University Hospital, Helsinki
The Christie NHS Foundation Trust, Manchester
Royal Cornwall Hospitals NHS Trust, Truro
Lead Sponsor
Faron Pharmaceuticals Ltd
INDUSTRY